Adagene's Muzastotug Posts Strong Clinical Data, Extends Cash Runway to Early 2028
ADAG has more than doubled off its 52-week low of $1.3.
Summary
Adagene reported positive full-year 2025 results and a significant corporate update, highlighting strong clinical data for its lead asset, muzastotug. The drug demonstrated a 29% overall response rate (ORR) in 20 mg/kg cohorts and a median overall survival (OS) of 19.4 months in 10 mg/kg cohorts for MSS CRC patients, comparing favorably to existing therapies. The company also reported a favorable safety profile with low discontinuation rates and no Grade 4 or 5 treatment-related adverse events. Furthermore, Adagene announced an extended cash runway into early 2028, bolstered by $74.5 million in cash and equivalents as of year-end 2025 and recent ATM proceeds. This robust clinical progress, coupled with a solid financial position and regulatory alignment (Fast Track, Project Optimus), significantly de-risks the development path for muzastotug towards a potential registrational trial, making this a highly material update for investors.
At the time of this announcement, ADAG was trading at $4.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $184.8M. The 52-week trading range was $1.30 to $4.72. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.